As obesity continues to reshape the cardiometabolic landscape, early-stage developers face growing pressure to generate decisive, translational evidence sooner. The condition is now widely recognised as a chronic metabolic disease with complex systemic effects across cardiovascular, metabolic, hepatic, and inflammatory pathways. In this environment, weight loss alone is no longer sufficient. Phase 1-2 trials are increasingly expected to deliver deeper biological insight to support confident development decisions.
On 12th May 2026 [14.00 BST, 15.00 CET, 9.00 EST] in a webinar sponsored by hVIVO, join two leading cardiometabolic experts – Professor Dr Thomas Forst, chief medical officer at hVIVO, and Esteban Jodar Gimeno, Head of the Endocrinology Department at University Hospitals Quiron Salud Madrid – to explore how early development programmes can be designed to generate meaningful pharmacodynamic evidence alongside safety and pharmacokinetics.
